In recent years, the morbidity and mortality of malignant tumors are increasing, and the incidence trend is younger. With the continuous development and application of chemotherapy drugs, chemotherapy has become one of the important means to treat tumors. Platinum drugs are the most commonly used non-specific anti-tumor drugs in the clinical treatment. Cisplatin (CCP) used in this study is a new platinum complex with supramolecular structure synthesized in China, aiming to investigate the effect of CCP on gastrointestinal tumors. The inhibitory effects of carboplatin and cisplatin on hepatocellular carcinoma, gastric cancer, colon cancer and embryonic lung fibroblast pancreatic cancer were determined by cell culture (IC50). The results showed that CCP and carboplatin (CBP) had significant inhibitory effects on liver cancer, stomach cancer, colon cancer and embryonic lung fibroblast pancreatic cancer, and the inhibitory effects were concentration-dependent. The IC50 value of CCP for liver cancer, stomach cancer, colon cancer and embryonic lung fibroblast pancreatic cancer was significantly lower than that of CBP(P<0.05), which was about 1/3∼1/2 of the IC50 value of carboplatin. Meanwhile, the IC50 value of CBP and CCP for embryonic lung fibroblast pancreatic cancer was both more than 240ml/L. It indicates that the supramolecular platinum drugs CCP have a significant inhibitory effect on gastrointestinal tumors, which is stronger than the clinical effect of CBP.
Read full abstract